Cargando…
A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults
Human immunodeficiency virus (HIV)-associated tuberculosis is a major public health threat. We evaluated the safety and immunogenicity of the candidate tuberculosis vaccine M72/AS01 in HIV-positive and HIV-negative Indian adults. Randomized, controlled observer-blind trial (NCT01262976). We assigned...
Autores principales: | Kumarasamy, Nagalingeswaran, Poongulali, Selvamuthu, Bollaerts, Anne, Moris, Philippe, Beulah, Faith Esther, Ayuk, Leo Njock, Demoitié, Marie-Ange, Jongert, Erik, Ofori-Anyinam, Opokua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998253/ https://www.ncbi.nlm.nih.gov/pubmed/26817879 http://dx.doi.org/10.1097/MD.0000000000002459 |
Ejemplares similares
-
Long-term safety and immunogenicity of the M72/AS01(E) candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial
por: Kumarasamy, Nagalingeswaran, et al.
Publicado: (2018) -
A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults
por: Montoya, Jaime, et al.
Publicado: (2013) -
Safety and immunogenicity of candidate vaccine M72/AS01(E) in adolescents in a TB endemic setting
por: Penn-Nicholson, Adam, et al.
Publicado: (2015) -
Impact of COVID-19 on people living with HIV: A review
por: Prabhu, Sandeep, et al.
Publicado: (2020) -
The F4/AS01(B) HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial
por: Dinges, Warren, et al.
Publicado: (2016)